Sofovir 400 mg Tablet + Daclahep 60 Tablet

Sofovir 400 mg Tablet + Daclahep 60 Tablet is a highly effective direct-acting antiviral (DAA) combination therapy developed for the treatment of chronic Hepatitis C Virus (HCV) infection. This combination contains Sofosbuvir 400 mg, marketed as Sofovir, and Daclatasvir 60 mg, marketed as Daclahep. Together, these antiviral medicines target different stages of the Hepatitis C virus life cycle, helping eliminate the virus from the body and significantly improving liver health. Due to its excellent clinical efficacy, high cure rates, and well-established safety profile, this combination has become one of the preferred treatment options for patients suffering from chronic Hepatitis C across the world.

Sofovir 400 mg contains Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor that directly interferes with the virus's ability to replicate its RNA. By blocking viral RNA synthesis, Sofosbuvir prevents the Hepatitis C virus from multiplying and spreading within the liver. Daclahep 60 mg contains Daclatasvir, an NS5A inhibitor that targets another essential viral protein responsible for viral replication and assembly. The dual mechanism of action offered by Sofosbuvir and Daclatasvir provides a powerful antiviral response, making the therapy effective against multiple Hepatitis C genotypes while reducing the likelihood of viral resistance.

This combination is commonly prescribed for adults diagnosed with Hepatitis C Genotypes 1, 2, 3, and 4, depending on the physician's assessment and the patient's clinical condition. The standard treatment duration is generally 12 weeks, although some patients, particularly those with liver cirrhosis or previous treatment failure, may require therapy for up to 24 weeks. Clinical studies have consistently demonstrated sustained virologic response (SVR) rates exceeding 95%, indicating that the virus becomes undetectable after successful completion of treatment in the vast majority of patients.

One of the greatest advantages of Sofovir and Daclahep therapy is its convenience and effectiveness. The medication is administered orally, usually as one Sofovir 400 mg tablet and one Daclahep 60 mg tablet once daily, with or without food, as directed by a healthcare professional. Taking the medication at the same time every day helps maintain consistent drug levels in the bloodstream and maximizes treatment success. Patients are advised to complete the full prescribed course even if they begin feeling better before treatment is finished.

Compared with older interferon-based therapies, this combination offers a significantly improved safety profile and is generally well tolerated. Some patients may experience mild side effects such as headache, fatigue, nausea, dizziness, weakness, insomnia, or mild gastrointestinal discomfort. These effects are usually temporary and resolve without medical intervention. Serious adverse reactions are uncommon when the medication is used under appropriate medical supervision. Regular monitoring of liver function and viral load may be recommended throughout the treatment period to ensure optimal therapeutic outcomes.

Patients should inform their healthcare provider about any existing liver disease, kidney disorders, HIV infection, hepatitis B infection, pregnancy, breastfeeding status, or any medications they are currently taking. Certain medicines may interact with Sofosbuvir or Daclatasvir and could require dosage adjustments or additional monitoring. Alcohol consumption should be avoided during treatment, as it may further damage the liver and reduce the effectiveness of antiviral therapy. Patients should always follow their physician's recommendations regarding dosage, treatment duration, and follow-up evaluations.

Sofovir 400 mg Tablet and Daclahep 60 Tablet should be stored in their original packaging in a cool, dry place below room temperature, protected from excessive heat, moisture, and direct sunlight. The medicines should remain out of reach of children and should not be used after their expiration date. Proper storage helps maintain the quality, stability, and effectiveness of the medication throughout its shelf life.

The combination of Sofosbuvir and Daclatasvir has transformed the management of chronic Hepatitis C by offering a highly successful, well-tolerated, and convenient oral treatment option. Successful therapy not only eliminates the virus but also reduces the risk of serious long-term complications, including liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Early diagnosis and timely treatment with this antiviral combination can significantly improve a patient's quality of life and long-term prognosis.

At Ayurmed Medicose, we are committed to supplying authentic, high-quality antiviral medicines that comply with international pharmaceutical standards. We source genuine Sofovir 400 mg Tablets and Daclahep 60 Tablets from trusted manufacturers, ensuring reliable quality, secure packaging, competitive pricing, and prompt worldwide delivery. With a strong commitment to customer satisfaction, product authenticity, and global pharmaceutical distribution, Ayurmed Medicose has established itself as a trusted partner for hospitals, pharmacies, healthcare professionals, wholesalers, and international buyers seeking dependable Hepatitis C treatment solutions. Our dedication to excellence ensures that every product delivered meets stringent quality standards while supporting better patient outcomes worldwide.